<DOC>
	<DOC>NCT02735980</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life.</brief_summary>
	<brief_title>A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Have EDSCLC and have received a prior platinumbased regimen Participants in Cohort 1 must have had an objective response to prior platinumbased therapy with subsequent progression â‰¥90 days after the last dose of platinum Participants in Cohort 2 must have either not had an objective response to prior platinum based therapy or had progression &lt;90 days after the last dose of platinum Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group scale Have received more than 2 prior therapies for EDSCLC (including immunotherapy, targeted therapies, or chemotherapy) Have symptomatic central nervous system (CNS) malignancy or metastasis. Asymptomatic participants with treated CNS metastases are eligible for this study if they are not currently receiving corticosteroids to treat CNS metastases Have previously completed or withdrawn from this study or any other study investigating prexasertib or a checkpoint kinase I (CHK1) inhibitor or have shown hypersensitivity to any of the components of the prexasertib formulation Have a serious cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>SCLC</keyword>
	<keyword>LY2606368</keyword>
	<keyword>CHK1</keyword>
</DOC>